Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer.
Invasive breast cancer of no special type
Prognosis
Spleen glucose metabolism
Stromal tumor-infiltrating lymphocytes
Total metabolic tumor volume
[18F]-FDG PET/CT
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
10
02
2021
accepted:
16
03
2021
pubmed:
29
3
2021
medline:
21
10
2021
entrez:
28
3
2021
Statut:
ppublish
Résumé
We evaluated whether biomarkers on baseline [ In this retrospective single-center study, we included consecutive patients with non-metastatic breast cancer of NST who underwent [ Three hundred and three women were eligible, including 93 (31%) with triple-negative breast carcinoma. After a median follow-up of 6.2 years, 56 and 35 patients experienced recurrence and death, respectively. The 5y-RFS rate was 86%. In multivariable analyses, high TMTV (>20 cm3) and high SLR (>0.76) were associated with shorter 5y-RFS (HR 2.4, 95%CI 1.3-4.5, and HR 1.9, 95%CI 1.0-3.6). In logistic regression, high SLR was the only independent factor associated with low stromal TILs (OR 2.8, 95%CI 1.4-5.7). High total metabolic tumor volume and high spleen glucose metabolism on baseline [
Identifiants
pubmed: 33774685
doi: 10.1007/s00259-021-05322-2
pii: 10.1007/s00259-021-05322-2
doi:
Substances chimiques
Biomarkers
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3560-3570Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007;13:3207–14.
pubmed: 17545524
doi: 10.1158/1078-0432.CCR-06-2765
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh I-T, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55–65.
pubmed: 20005174
doi: 10.1016/S1470-2045(09)70314-6
Lee SH, Ha S, An HJ, Lee JS, Han W, Im S-A, et al. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer. Eur J Nucl Med Mol Imaging. 2016;43:1574–84.
pubmed: 27209424
doi: 10.1007/s00259-016-3418-1
Buus R, Sestak I, Kronenwett R, Ferree S, Schnabel CA, Baehner FL, et al. Molecular drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: a TransATAC study. J Clin Oncol. 2021;39:126–35.
pubmed: 33108242
doi: 10.1200/JCO.20.00853
Ko H, Baghdadi Y, Love C, Sparano JA. Clinical utility of 18F-FDG PET/CT in staging localized breast cancer before initiating preoperative systemic therapy. J Natl Compr Cancer Netw. 2020;18:1240–6.
doi: 10.6004/jnccn.2020.7592
Hyland CJ, Varghese F, Yau C, Beckwith H, Khoury K, Varnado W, et al. Use of 18F-FDG PET/CT as an initial staging procedure for stage II-III breast cancer: a multicenter value analysis. J Natl Compr Cancer Netw. 2020;18:1510–7.
doi: 10.6004/jnccn.2020.7598
Nakajo M, Kajiya Y, Kaneko T, Kaneko Y, Takasaki T, Tani A, et al. FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging. 2010;37:2011–20.
pubmed: 20607535
doi: 10.1007/s00259-010-1529-7
Groheux D, Giacchetti S, Moretti J-L, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426–35.
pubmed: 21057787
doi: 10.1007/s00259-010-1640-9
Koo HR, Park JS, Kang KW, Han W, Park IA, Moon WK. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer. Eur Radiol. 2015;25:3314–21.
pubmed: 25903708
doi: 10.1007/s00330-015-3734-z
Nishimukai A, Inoue N, Kira A, Takeda M, Morimoto K, Araki K, et al. Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers. PLoS One. 2017;12:e0184508.
pubmed: 28886153
pmcid: 5590948
doi: 10.1371/journal.pone.0184508
Kitajima K, Yamano T, Fukushima K, Miyoshi Y, Hirota S, Kawanaka Y, et al. Correlation of the SUVmax of FDG-PET and ADC values of diffusion-weighted MR imaging with pathologic prognostic factors in breast carcinoma. Eur J Radiol. 2016;85:943–9.
pubmed: 27130054
doi: 10.1016/j.ejrad.2016.02.015
pmcid: 27130054
Yoo J, Yoon H-J, Kim BS. Prognostic value of primary tumor SUVmax on F-18 FDG PET/CT compared with semi-quantitative tumor uptake on Tc-99m sestamibi breast-specific gamma imaging in invasive ductal breast cancer. Ann Nucl Med. 2017;31:19–28.
pubmed: 27645144
doi: 10.1007/s12149-016-1127-2
pmcid: 27645144
Diao W, Tian F, Jia Z. The prognostic value of SUVmax measuring on primary lesion and ALN by 18F-FDG PET or PET/CT in patients with breast cancer. Eur J Radiol. 2018;105:1–7.
pubmed: 30017264
doi: 10.1016/j.ejrad.2018.05.014
pmcid: 30017264
Jiménez-Ballvé A, García García-Esquinas M, Salsidua-Arroyo O, Serrano-Palacio A, García-Sáenz JA, Ortega Candil A, et al. Prognostic value of metabolic tumour volume and total lesion glycolysis in 18F-FDG PET/CT scans in locally advanced breast cancer staging. Rev Esp Med Nucl Imagen Mol. 2016;35:365–72.
pubmed: 26948652
pmcid: 26948652
Higuchi T, Fujimoto Y, Ozawa H, Bun A, Fukui R, Miyagawa Y, et al. Significance of metabolic tumor volume at baseline and reduction of mean standardized uptake value in 18F-FDG-PET/CT imaging for predicting pathological complete response in breast cancers treated with preoperative chemotherapy. Ann Surg Oncol. 2019;26:2175–83.
pubmed: 30941655
pmcid: 6545174
doi: 10.1245/s10434-019-07325-8
Lemarignier C, Martineau A, Teixeira L, Vercellino L, Espié M, Merlet P, et al. Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:1145–54.
pubmed: 28188325
doi: 10.1007/s00259-017-3641-4
pmcid: 28188325
Seban R-D, Robert C, Dercle L, Yeh R, Dunant A, Reuze S, et al. Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy. Oncoimmunology. 2019;8:e1574197.
pubmed: 31069132
pmcid: 6492982
doi: 10.1080/2162402X.2019.1574197
Seban R-D, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S, et al. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging. 2019;46:2298–310.
pubmed: 31346755
doi: 10.1007/s00259-019-04411-7
pmcid: 31346755
Seban R-D, Moya-Plana A, Antonios L, Yeh R, Marabelle A, Deutsch E, et al. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. Eur J Nucl Med Mol Imaging. 2020.
Wong A, Callahan J, Keyaerts M, Neyns B, Mangana J, Aberle S, et al. 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging. 2020;20:36.
pubmed: 32408884
pmcid: 7227105
doi: 10.1186/s40644-020-00313-2
Prigent K, Lasnon C, Ezine E, Janson M, Coudrais N, Joly E, et al. Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients. Eur J Nucl Med Mol Imaging. 2021.
Şahin E, Elboğa U. Relationship between reticuloendothelial systems’ FDG uptake level and clinicopathological features in patient with invasive ductal breast cancer. Radiol Med. 2017;122:785–92.
pubmed: 28597239
doi: 10.1007/s11547-017-0779-x
Bang J-I, Yoon H-J, Kim BS. Clinical utility of FDG uptake within reticuloendothelial system on F-18 FDG PET/CT for prediction of tumor recurrence in breast cancer. PLoS One. 2018;13:e0208861.
pubmed: 30532215
pmcid: 6286142
doi: 10.1371/journal.pone.0208861
Lee JW, Kim SY, Han SW, Lee JE, Lee HJ, Heo NH, et al. [18F]FDG uptake of bone marrow on PET/CT for predicting distant recurrence in breast cancer patients after surgical resection. EJNMMI Res. 2020;10:72.
pubmed: 32607957
pmcid: 7326752
doi: 10.1186/s13550-020-00660-y
Lee JW, Lee M-S, Chung IK, Son MW, Cho YS, Lee SM. Clinical implication of FDG uptake of bone marrow on PET/CT in gastric cancer patients with surgical resection. World J Gastroenterol. 2017;23:2385–95.
pubmed: 28428718
pmcid: 5385405
doi: 10.3748/wjg.v23.i13.2385
Yoon H-J, Kim BS, Moon CM, Yoo J, Lee KE, Kim Y. Prognostic value of diffuse splenic FDG uptake on PET/CT in patients with gastric cancer. PLoS One. 2018;13:e0196110.
pubmed: 29698422
pmcid: 5919642
doi: 10.1371/journal.pone.0196110
Lee JW, Choi JS, Lyu J, Lee SM. Prognostic significance of 18F-fluorodeoxyglucose uptake of bone marrow measured on positron emission tomography in patients with small cell lung cancer. Lung Cancer. 2018;118:41–7.
pubmed: 29572001
doi: 10.1016/j.lungcan.2018.01.020
Jeong H, Hwang I, Kang SH, Shin HC, Kwon SY. Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer. J Breast Cancer. 2019;22:38–51.
pubmed: 30941232
pmcid: 6438840
doi: 10.4048/jbc.2019.22.e5
Hashemi V, Maleki LA, Esmaily M, Masjedi A, Ghalamfarsa G, Namdar A, et al. Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target. Int Immunopharmacol. 2020;78:106087.
pubmed: 31841758
doi: 10.1016/j.intimp.2019.106087
Alshetaiwi H, Pervolarakis N, McIntyre LL, Ma D, Nguyen Q, Rath JA, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020;5.
Seban R-D, Champion L, Schwartz LH, Dercle L. Spleen glucose metabolism on [18F]-FDG PET/CT: a dynamic double-edged biomarker predicting outcome in cancer patients. Eur J Nucl Med Mol Imaging. 2021.
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–9.
pubmed: 28094848
doi: 10.3322/caac.21388
Cserni G, Chmielik E, Cserni B, Tot T. The new TNM-based staging of breast cancer. Virchows Arch. 2018;472:697–703.
pubmed: 29380126
doi: 10.1007/s00428-018-2301-9
pmcid: 29380126
Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860–7.
pubmed: 23341518
doi: 10.1200/JCO.2011.41.0902
pmcid: 23341518
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22:1736–47.
pubmed: 21709140
pmcid: 3144634
doi: 10.1093/annonc/mdr304
Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.
pubmed: 25452219
doi: 10.1007/s00259-014-2961-x
pmcid: 25452219
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–6.
pubmed: 8889347
doi: 10.1016/0197-2456(96)00075-X
pmcid: 8889347
Viallon V, Latouche A. Discrimination measures for survival outcomes: connection between the AUC and the predictiveness curve. Biom J. 2011;53:217–36.
pubmed: 21308725
doi: 10.1002/bimj.201000153
pmcid: 21308725
Empereur-Mot C, Guillemain H, Latouche A, Zagury J-F, Viallon V, Montes M. Predictiveness curves in virtual screening. J Cheminform. 2015;7:52.
pubmed: 26539250
pmcid: 4631717
doi: 10.1186/s13321-015-0100-8
Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol. 2013;66:648–53.
pubmed: 23415868
doi: 10.1016/j.jclinepi.2012.09.017
pmcid: 23415868
R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: 2020; Available from: https://www.R-project.org
Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83:878–86.
pubmed: 22172903
doi: 10.1016/j.ijrobp.2011.08.036
pmcid: 22172903
Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50.
pubmed: 29233559
doi: 10.1016/S1470-2045(17)30904-X
pmcid: 29233559
Annaratone L, Cascardi E, Vissio E, Sarotto I, Chmielik E, Sapino A, et al. The multifaceted nature of tumor microenvironment in breast carcinomas. Pathobiology. 2020;87:125–42.
pubmed: 32325459
doi: 10.1159/000507055
pmcid: 32325459
Christmas BJ, Rafie CI, Hopkins AC, Scott BA, Ma HS, Cruz KA, et al. Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. Cancer Immunol Res. 2018;6:1561–77.
pubmed: 30341213
pmcid: 6279584
doi: 10.1158/2326-6066.CIR-18-0070
Seban R-D, Assié J-B, Giroux-Leprieur E, Massiani M-A, Soussan M, Bonardel G, et al. Association of the metabolic score using baseline FDG-PET/CT and dNLR with immunotherapy outcomes in advanced NSCLC patients treated with first-line pembrolizumab. Cancers. Multidisciplinary Digital Publishing Institute; 2020;12:2234.
Tylski P, Stute S, Grotus N, Doyeux K, Hapdey S, Gardin I, et al. Comparative assessment of methods for estimating tumor volume and standardized uptake value in (18)F-FDG PET. J Nucl Med. 2010;51:268–76.
pubmed: 20080896
doi: 10.2967/jnumed.109.066241
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Annals of Oncology Elsevier. 2019;30:1194–220.
doi: 10.1093/annonc/mdz173
McLemore LE, Janakiram M, Albanese J, Shapiro N, Lo Y, Zang X, et al. An immunoscore using PD-L1, CD68, and tumor-infiltrating lymphocytes (TILs) to predict response to neoadjuvant chemotherapy in invasive breast cancer. Appl Immunohistochem Mol Morphol. 2018;26:611–9.
pubmed: 28422766
doi: 10.1097/PAI.0000000000000485
Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res. 2015;3:326–32.
pubmed: 25527356
doi: 10.1158/2326-6066.CIR-14-0133
Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852–8.
pubmed: 30478423
doi: 10.1038/s41591-018-0255-8